Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial

Background: Improved patient-reported outcomes (PROs) are increasingly becoming a key treatment objective in acromegaly. Validated PROs were used to assess disease and treatment burden in the MPOWERED phase 3 trial in acromegaly, which also assessed safety and efficacy of oral octreotide capsules (O...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Endocrine Society 2021-05, Vol.5 (Supplement_1), p.A520-A521
Main Authors: Gordon, Murray B, Fleseriu, Maria, Dreval, Akexander V, Pokramovich, Yulia, Bondar, Irina, Isaeva, Elena, Molitch, Mark E, Macut, Djuro P, Leonova, Nina, Raverot, Gerald, Kirschner, Lawrence S, Chanson, Philippe, Gilgun-Sherki, Yossi, Ludlam, William H, Patou, Gary, Haviv, Asi, Biermasz, Nienke, Melmed, Shlomo, Strasburger, Christian J
Format: Article
Language:English
Subjects:
Neuroendocrinology and Pituitary
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Improved patient-reported outcomes (PROs) are increasingly becoming a key treatment objective in acromegaly. Validated PROs were used to assess disease and treatment burden in the MPOWERED phase 3 trial in acromegaly, which also assessed safety and efficacy of oral octreotide capsules (OOC; MYCAPSSA®) compared to injectable SRLs (iSRLs). Methods: Eligible patients had acromegaly diagnosis, biochemical control of acromegaly (insulin-like growth factor I
ISSN:2472-1972
2472-1972
DOI:10.1210/jendso/bvab048.1062